Member Info for shandypants2

ok apologies - i'll rephrase then. Opti appear to have made no progress accessing the NHS's £600m p.a spend on OTC products.

As statins have limited benefit but are prescribed like smarties and Opti products have proven cholesterol lowering benefits this is disappointing.

Incidentally I asked this question to Opti directly at a trade fair 6 months ago and they told me this wasn't currently an area they were exploring - so don't shoot the messenger

Soup - not trying to be negative, just making an observation. I only comment on stocks I have a holding in so clearly I want this to rise and it has great potential to do so.
However, as stated Admin expenses (this will include wages) was £911,683 so it is far to assume similar now - so c£75k a month (not just wages, building costs, utilities etc). NFX had £4k in cash as at 31/3 (fact) and £500k came in in May, So it is fair to state that money is/was tight during this period.

Look at the last consolidated cashflow statement - net cashflow was -£300k last year but this included £975k of 'share and warrant based payments'. Who knows what this is now but it is clear the company relies on these to stay cashflow positive.

My initial comment was in relation to the Chinese money. It is required and it is needed ASAP. My opinion is unchanged

Similarly - did Ebers deal generate upfront £500k? If so why wasn't this in the RNS? Total rev for NFX was £610k last year so this is clearly material.

agree Cadbury I think we'll be ok for next year or so - H2 rev expected to double (and gross margin should increase accordingly) do there will be a bigger gross profit. This will reduce the loss and so hopefully cashburn too.
2020 should be a pivotal year and I think there is sufficient cash to fulfil all requirements

BTW the re-read last RNS - and new headsets is 12 not 6, apologies. rest of my comments are unchanged though.

Theatres would be a great addition. I've been to a few museums and other attractions (London Eye, Science museum etc) where you pay extra for say a 4d experience. 10 minute 3d film with some water or air blown at you! Overpriced and underwhelming really but the kids love them. Now a VR alternative would be much more attractive IMHO

Taff and Soup - yes we received £500k in May but NFX lost £1.6m last year including £910k admin costs.
We are now in Oct, 6 months on from 31/3 when we had cash of £4k, so that £500k has pretty much been spent on wages.

That £2m payment is needed ASAP. The numbers don't lie

as opti products are defined as foods rather than drugs these products will never be available on the NHS imho.

I do think one day they will be declared a 'wonder food' though

Taff - check the cashflow statement in the annual accounts - apology accepted

not trying to be negative just pointing out the obvious - the delay in payment (which was due in June) is having an adverse impact on the share price and cash is tight - on 31/3 as per annual statement we had 4,261 (there is no k!!).

Another placing will not be viewed positively too regardless of NFX's potential.

surely this is good. The potential elephant in the room has been removed and we can move on.

I think share price hasn't risen much because we are still awaiting a RNS announcing a big order. There are a number in the pipeline - just a matter of time IMHO

Bottmzup - I believe the 33 have been previously RNSed.

The recent RNS detailed 6 new headset agreements. The likelihood is these are trials and additional orders may be made but I'm a little surprised this warranted an RNS (price sensitive info etc).

Clearly the company is moving in the right direction and the quality over quantity approach is clearly paying dividends. I firmly believe that the company will be breakeven in Q1 2020 (possibly earlier) and will be making decent profits soon after.

However, 1,000 headsets does seem a big ask.

Merlin Entertainment has c70 venues (theme parks, dungeons, sea life, madame tussauds etc). We are in a few of these. If a big announcement dropped that we are rolling out VR to everyone of these it might increase headsets by say 200.

Similarly, current pipeline of 50 enquiries might yield say 100 new orders.

All great progress but we currently have c300 so will be surprised if it is more than say 600 to 700 end of 2020 IMHO.

Incidentally already I quite like the CEO I have learned from bitter experience not to trust everything a CEO says!

I think you are being very generous.

We don't know what the performance targets are so difficult to say if good or bad, but I think a £220k annual incentive on top of salary is very generous for a listed CEO. Also if share say rises 10% a year (not a big ask) that £220k is well over £300k in year 5.

Share options - if he exercises these clearly the price will be significantly higher than now. He can merely 'flip' these immediately and not pay a penny and just take the profit. That's usually how share options work - they are not warrants where the company would at least get some money for issuing new shares.

with no chinese payment this could slip sub 6p until new drops IMHO.

great potential but needs some newsflow - and it looks like short term Chinese uncertainty won't now be resolved until mid Oct at the earliest

I saw the RNS differently. I think GFIN weren't expecting much revenue from websites but it has been pleasantly surprised.

It's also not 10% now - it's 10% by 2021 and 2021 is meant to be breakeven.

So not sure why this is considered a negative IMHO

unfortunately with this cash burn another placing is inevitable.

Great product but terrible marketing.

it was expected but was hoping it would be after JORC and therefore at a higher price

Itx has said H2 will be double H1 revenue. What more do u want?

I think the assays were always going to be a 'dry' rns and were never going to be the big reveal.

However, the JORC is key, but this is produced independently, LR has to keep tight lipped and not display any emotion.

I think based on the data they have they are expecting it be positive but can't say so ATM. Less than 4 weeks to go - sit on your hands! . Did a little cheeky top up this morning - didn't think I'd see O.O3s again - and we won't in a few weeks!

only £100k cash left though

should say HOPING a rns drops next week!

RNS will drop next week. Hoping new lab space is good to go any day now (were told end of Q3 so shouldn't be far off), SKIN has been to loads of trade fairs and presentations over the last month so these leads will have been worked and then there are the big contract discussions (£1m region) mentioned by chairman in interims.

I think a new contract will need to be >£50k plus to be a RNS but a 4 contracts worth £100k plus would surely be acceptable. SKIN is valued at £17m so GB needs to show us that revenues are continuing to grow rapidly.
So far he has done this